Sunitinib is an oral pill that is in trials for NF2, with expectations of the reduction in size of Meningiomas.
Side effects have been found to be minimal and any severe issues disappear with dose reduction, break in treatment or other treatment.
This is a new NF2 treatment and facts collected are based on use of Sunitinib for other treatments. Sunitinib has been found more effective in situations where Sorafenib (Nexavar), Temsirolimus (Torisel), Interleukin-2 (Proleukin), Everolimus (Afinitor), Bevacizumab (Avastin) and Aldesleukin helped, but they only had minimal effect.
|Other Names||Sutent, SU-11248, sunitinibum, Sunitinib (INN), Su-011248, SU11248, SU 11248, CHEBI:38940, Sunitinib (free base), Sunitinib Malate|
|Treatment By||Pill - Oral|
|Tumor Target||Intracranial Meningioma|
|Interactions||Avoid Grapefruit and Green Tea|
|Expectation||Size reduction of Meningiomas Multi-targeted Receptor Tyrosine Kinase (RTK) Inhibitor|
|Inhibits VEGF-R2 and PDGF-Rbeta tyrosine kinase; has antineoplastic activity; structure in first source|
|ChemSpider||4486264 (accessed 16:29, Oct 11, 2012)|
|1.||Trial Name||Sunitinib in Treating Patients With Recurrent or Unresectable Meningioma, Intracranial Hemangiopericytoma, or Intracranial Hemangioblastoma|
|Condition||Brain and CNS Tumors||Phase||Phase 2|
|Collaborator||National Cancer Institute (NCI)||Sponsor||Memorial Sloan-Kettering Cancer Center|
|2.||Trial Name||Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma|
|Sponsors and Collaborators||Dana-Farber Cancer Institute, University of Virginia, University of Pittsburgh and Pfizer||Principal Investigator||Memorial Sloan-Kettering Cancer Center, New York|
Sunitinib is Chemically similar to Imatinib. Imatinib has been used to treat other conditions that did not generally respond to standard chemotherapy or radiation, but while some people did not respond to it, 50% developed a resistance to its effects within 2 years. For those conditions, Sunitinib was started after Imatinib resistance was developed till conclusion was that Sunitinib was simply a more effective treatment. Sunitinib reduced the relative risk of disease progression or death by a considerable percentage.
Size reduction of Meningiomas.
Major side effects are uncommon. Since people with NF2 are taking these medications at a low dose, only minimal side effects would likly happen. However, long term use is primarily where these major side effects take place. Monthly Blood and Urine Tests can usually point to an issue before any issues are a real problem. Talk to your doctor.
|US20090118240A1||07-02-2012||LOCAL TREATMENT OF NEUROFIBROMAS LOCAL TREATMENT OF NEUROFIBROMAS|
|US20090318525A1||04-09-2012||Process For Preparing A 3-Pyrrole Substituted 2-Indolinone Malate Salt Process For Preparing A 3-Pyrrole Substituted 2-Indolinone Malate Salt|
|US20100143946A1||04-02-2012||ALPHA-SYNUCLEIN KINASE ALPHA-SYNUCLEIN KINASE|
|US20120029046A1||02-01-2012||CRYSTALLINE FORM OF SUNITINIB AND PROCESSES FOR ITS PREPARATION|
|US20110306647A1||12-14-2011||NOVEL POLYMORPHS OF SUNITINIB MALATE|
Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with
any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here,
the accuracy of other sites to which this site links, or of sites that link to this site. - Read More
Copyright © 2008 - 2017